Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

March 28, 2024

Huntsman Cancer Institute at the University of Utah received $75 million from the Utah Legislature toward a cancer research and academic building.

March 26, 2024

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

March 25, 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

March 25, 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

March 18, 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

March 18, 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

March 11, 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

March 11, 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

March 04, 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

March 04, 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

February 26, 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

February 26, 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

February 21, 2024

Jonathan Constance, PhD, and his team have created a digital pharmacology platform for assessing drug dynamics directly among children with cancer.

February 19, 2024

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

February 07, 2024

Huntsman Cancer Institute introduces the first and only single-port robot in the Mountain West for head and neck surgical oncology patients.

January 23, 2024

Huntsman Cancer Institute has appointed new roles for Theresa Werner, MD, and Neeraj Agarwal, MD, FASCO.

January 14, 2024

Doctors diagnosed Christopher Gregg, PhD, with stage IV metastatic breast cancer in 2018. Then, he started thinking of ways to improve his treatment.

January 10, 2024

Alana Welm, PhD, received the 2023 American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research.

January 04, 2024

The oral XPO1 inhibitor selinexor in combination with ruxolitinib was associated with a tolerable and manageable adverse effect profile and elicited signals of clinical efficacy in patients with JAK inhibitor–naive myelofibrosis.

December 27, 2023

Researchers at Huntsman Cancer Institute at the University of Utah discovered that the level of blood and immune cells in mouse model offspring would fluctuate based on the amount of folic acid consumed by their mothers during pregnancy.